Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02981342 · ClinicalTrials.gov registry record · Phase 2
A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 106
- Enrollment target
NCT02981342 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 106 participants.
The verdict
NCT02981342, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 106 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of abemaciclib alone and in combination with other drugs versus standard of care in participants with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC).
Interventions
- DRUG Capecitabine
- DRUG Abemaciclib
- DRUG Gemcitabine
- DRUG LY3023414
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2017-01-12 |
| Est. Completion | 2018-11-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02981342
The ClinicalTrials.gov registry entry for NCT02981342 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 106 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Capecitabine is the first listed.
NCT02981342 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02981342 about?
NCT02981342 is a clinical study titled "A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma". The purpose of this study is to evaluate the safety and efficacy of abemaciclib alone and in combination with other drugs versus standard of care in participants with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC).
What is the current status of trial NCT02981342?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 106 participants. The study started on 2017-01-12. Estimated completion is 2018-11-09.
What interventions are being tested in trial NCT02981342?
The interventions under investigation include: Capecitabine (DRUG), Abemaciclib (DRUG), Gemcitabine (DRUG), LY3023414 (DRUG).
Who is sponsoring clinical trial NCT02981342?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.